Acer Therapeutics rises on FDA nod to start menopausal symptoms drug trial

Acer Therapeutics

09/12/2021 17:24

** Shares of drug developer Acer Therapeutics  ACER.O  up
~2% at $2.18 
    ** U.S. FDA accepts co's application to start human trials
for its drug candidate, ACER-801, for treatment of induced
vasomotor symptoms  urn:newsml:reuters.com:*:nGNXb9wf41 
    ** Vasomotor symptoms, including hot flashes and night
sweats, are commonly associated with menopause in women
    ** Co plans to start mid-stage study in Q1 2022 to evaluate
safety and efficacy of different doses of ACER-801 and its
effect on the frequency and severity of vasomotor symptoms
    ** Including session's moves, stock down 16.79% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))